Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14683171 | 0.85 | — | — | |
| SCHEMBL17650908 | 0.85 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL17650996 | 0.85 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL23240165 | 0.81 | GABRA1 (0.32) | GABRA1GABRB2MIF | |
| SCHEMBL25573712 | 0.81 | GABRA1 (0.36) | GABRA1GABRB2MIF | |
| SCHEMBL11555693 | 0.81 | GABRA1 (0.36) | GABRA1GABRB2MIF | |
| SCHEMBL28374773 | 0.81 | TAAR1 (0.35) | GABRA1GABRB2MIF | |
| SCHEMBL3612484 | 0.80 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL17650044 | 0.78 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL2824472 | 0.77 | MIF (0.44) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084759-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2025-03-13 | — | — | US | claimed |
| CN-115411362-A | Electrolyte for lithium ion battery, lithium ion battery and preparation method thereof | 江苏海四达电源有限公司 | 2022-11-29 | — | — | CN | claimed |
| US-20250084759-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2025-03-13 | — | — | US | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-12215108-B2 | Development of potential antidotes for arsenicals | SOUTHERN RESEARCH INSTITUTE (US) | 2025-02-04 | — | — | US | disclosed |
| US-12188350-B2 | Fluorescent dye oil tracer compositions | SAUDI ARABIAN OIL COMPANY (SA) | 2025-01-07 | — | — | US | disclosed |
| CN-115557908-B | Triazine derivative containing sulfur connecting bond, and synthesis method and application thereof | 九江学院 | 2024-10-15 | — | — | CN | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230399942-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-12-14 | — | — | US | disclosed |
| US-20230399942-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-12-14 | — | — | US | disclosed |
| WO-2006122769-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122770-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| US-5914343-A | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, HOST VERSUS GRAFT REJECTION | SUGEN, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5760066-A | AIDS, ATHEROSCLEROSIS, CANCER | SUGEN, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1996033179-A1 | THIOAMIDES DERIVATES AND THEIR USE AS INHIBITORS OF HYPER-PROLIFERATIVE CELL GROWTH | SUGEN, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0227088-B1 | ISOXAZOLO-NAPHTHYRIDINE, ISOXAZOLO QUINOLINE, ISOTHIAZOLONAPHTHYRIDINE, AND ISOTHIAZOLOQUINOLINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| US-4767762-A | Tricyclic quinoline and naphthyride antibacterials | ABBOTT LABORATORIES (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0227088-A1 | Isoxazolo-naphthyridine, isoxazolo quinoline, isothiazolonaphthyridine, and isothiazoloquinoline derivatives | ABBOTT LABORATORIES (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4138242-A | Novel 2-aryl-2,3,5,6,7,8-hexahydro-3-thioxoimidazo-[1,5-a-]pyridin-1(BaH)-ones as herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215108-B2 | Development of potential antidotes for arsenicals | RIPK1, RIPK3, RIPK4 | GABRA1 4145/4885GABRB2 3581/4885MIF 4647/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | GABRA1 2836/4885GABRB2 2757/4885MIF 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.